Profusa (NASDAQ:PFSA – Get Free Report) issued its earnings results on Friday. The company reported ($6.23) earnings per share for the quarter, FiscalAI reports.
Profusa Stock Performance
Shares of Profusa stock traded down $0.01 on Friday, hitting $0.45. 406,350 shares of the company traded hands, compared to its average volume of 1,100,146. Profusa has a 52 week low of $0.40 and a 52 week high of $1,539.75. The business has a 50-day simple moving average of $1.47 and a 200 day simple moving average of $66.63. The stock has a market capitalization of $273,280.00, a P/E ratio of -0.00 and a beta of 0.62.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on PFSA shares. Wall Street Zen raised Profusa to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings upgraded Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
View Our Latest Report on PFSA
About Profusa
Profusa, Inc. is a biotechnology and medical-device company focused on developing implantable biosensors designed to continuously monitor biochemical conditions inside the body. Its technology is intended to provide real-time health data without requiring repeated blood draws or external sampling. The company’s biosensors are designed to be placed under the skin and remain in the body while communicating measurements to an external reader or connected device. Profusa has developed platforms intended to monitor markers such as tissue oxygen levels, with potential applications in areas including peripheral artery disease, wound care, chronic disease management and clinical research.
Read More
- Five stocks we like better than Profusa
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
